Innovative Microfluidics Miroculus has developed the Miro Canvas platform, a compact and user-friendly digital microfluidics system that automates complex NGS protocols, making advanced genomics research more accessible to laboratories of all sizes.

Growing Market Presence Since launching Miro Canvas in early 2022, Miroculus has garnered significant attention, including a strategic acquisition by INTEGRA Biosciences in March 2023, positioning it for expanded market reach and enhanced product integration opportunities.

Strategic Collaborations Partnerships with companies like Element Biosciences demonstrate Miroculus's capability to integrate its microfluidics platform with innovative sequencing systems, offering potential for joint sales and bundled solutions to target high-growth NGS application areas.

Investment & Financial Strength With revenue estimated between $50 million and $100 million and recent funding of $45 million, Miroculus has the financial backing to support sales expansion and the development of new automation solutions tailored to customer needs.

Technological Leadership Miroculus's focus on simplifying complex genomics protocols through intuitive tools offers a compelling value proposition for labs seeking automation, automation, and efficiency, creating strong opportunities for targeted sales pitches to research institutions and biotech firms.